Skip to content

Durban – Aspen, a global multinational specialty pharmaceutical company, was extremely disappointed to learn over the past weekend that specific batches of the Johnson & Johnson COVID-19 vaccine manufactured at our Gqeberha production site and designated for the South African market have to be destroyed due to the Good Manufacturing Practice risk of isolated material…

Read More

Pretoria – The Chevalier de l’Ordre national du Mérite (Knight of the French National Order of Merit) was bestowed upon Stephen Saad, Aspen’s Group Chief Executive, at the University of Pretoria earlier today.  The national order, originally announced on 11 March 2019, was presented by President Emmanuel Macron at a small event with limited guests…

Read More

Pretoria, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today participated in a high-level manufacturing seminar on manufacturing vaccines in Africa, hosted by South African President Cyril Ramaphosa and French President Emmanuel Macron.

Read More

Aspen joins the country and the medical fraternity in mourning the passing of Dr Sindi van Zyl, a dedicated and significant contributor to our country’s healthcare system. Dr Van Zyl will always be remembered for her ongoing involvement in helping our country in fighting the HIV/AIDS pandemic as a compassionate doctor and, an HIV clinician.…

Read More

Stephen Saad’s address on the occasion of President Cyril Ramaphosa’s visit at our Sterile Facility in the Eastern Cape at which time he announced the agreement reached with Johnson & Johnson to supply 250 million covid-19 vaccines to Africa, with 30 million being for South Africa

Read More

Gqeberha, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today hosted President Cyril Ramaphosa and an accompanying government delegation at its flagship manufacturing site in the Eastern Cape. Aspen has invested in excess of R3.0 billion at this sterile manufacturing site, the single largest investment in the pharmaceutical industry in South Africa. The new…

Read More

“Our Aspen philosophy has always been to give purpose to life. This is best achieved by contributing meaningfully to others. Aspen has defined itself and continues to define itself as a company that serves humanity, particularly the most vulnerable amongst us. It was over a decade ago that we made a special announcement on a…

Read More

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 30 December 2021. Stephen Saad, Aspen Group Chief Executive said, “The business has delivered pleasing results and has proven to be in robust shape over the past six…

Read More

Durban – United States-based Aspen Pharma USA Inc. and Aspen Global Incorporated, located in Mauritius, both wholly owned subsidiaries of Aspen Pharmacare Holdings Limited, have announced a license and commercialisation agreement with Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, for the exclusive rights to relaunch Cenestin® in the USA. This is a New Drug Application…

Read More

Durban, South Africa – Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited (which trades as “Aspen Pharmacare”), has entered into a preliminary agreement with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the technical transfer and proposed commercial…

Read More
Scroll To Top